Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study

doi:10.18632/oncotarget.10450

科研成果详情

题名	Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study
作者	Zhao, Hongqin1; Li, Lili2; Su, Huafang2; Lin, Baochai2; Zhang, Xuebang2; Xue, Shengliu2; Fei, Zhenghua2; Zhao, Lihao2; Pan, Qintuo3; Jin, Xiance2; Xie, Congying2
发表日期	2016-10-25
发表期刊	ONCOTARGET 影响因子和分区
语种	英语
原始文献类型	Article
关键词	cervical cancer chemoradiotherapy consolidation chemotherapy cisplatin paclitaxel
其他关键词	GYNECOLOGIC-ONCOLOGY-GROUP ; SQUAMOUS-CELL CARCINOMA ; RADIATION-THERAPY ; PELVIC IRRADIATION ; PLUS CISPLATIN ; IVA CARCINOMA ; TRIAL ; RADIOTHERAPY ; GEMCITABINE ; SURVIVAL
摘要	A phase III randomized study on the efficacy and safety of consolidation chemotherapy with paclitaxel plus cisplatin following radical hysterectomy and adjuvant chemoradiotherapy (CRT) in the treatment of high risk early-stage cervical cancer were reported. 146 eligible patients were randomized to arm A receiving concurrent CRT or arm B receiving CRT plus consolidation chemotherapy, respectively. An interim analysis showed a trend of improvement on disease-free survival (DFS) and overall survival (OS) in arm B with hazard ratios (HR) of 1.25 (95% CI = 0.60-2.60, p = 0.55) and 1.43 (95% CI = 0.64-3.20, p = 0.38) for DFS and OS, respectively. The 3-year DFS and OS were 82.0% vs. 74.3%, and 86.6% vs. 78.3% for patients receiving CRT plus consolidation chemotherapy and CRT alone, respectively. There was significant difference between the two arms in distant alone recurrence (p = 0.048). Multivariate analysis indicated that pathologic type was a significant prognostic factor for OS (p = 0.045), positive pelvic nodes were significantly associated with both OS (p= 0.02) and DFS (P= 0.03). Grade 2 to 4 gastrointestinal disorder (p = 0.95), radiation enteritis (P= 0.48), radiation cystitis (p = 0.27) and radioepidermitis (p = 0.46) were similar in the two arms. Overall rates of grade 0-2/3-4 myelosuppression were 87.7%/12.3% for arm A and 74.6%/25.4% for arm B, respectively, but this difference was not statistically significant (p = 0.05). In conclusion, concurrent CRT plus consolidation chemotherapy may play a potential role in further improving survival outcomes for high- risk early stage cervical cancer patients compared CRT alone.
资助项目	Wenzhou Municipal Science and Technology Bureau [H20100068]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY16H160047]; [Y20140709]
出版者	IMPACT JOURNALS LLC
出版地	ORCHARD PARK
ISSN	1949-2553
EISSN	1949-2553
卷号	7 期号:43 页码:70969-70978
DOI	10.18632/oncotarget.10450
页数	10
WOS类目	Oncology ; Cell Biology
WOS研究方向	Oncology ; Cell Biology
WOS记录号	WOS:000387448300143
收录类别	SCIE ; PUBMED ; SCOPUS
URL	查看原文
PubMed ID	27391158
PMC记录号	PMC5342602
SCOPUSEID	2-s2.0-84994300355
通讯作者地址	[Jin, Xiance]Departments of Radiation Oncology and Chemotherapy,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou,325000,China
Scopus学科分类	Oncology
引用统计	被引频次：13[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/12870
专题	第一临床医学院（信息与工程学院）、附属第一医院_妇产科学_妇科附属第一医院_放化疗科眼视光学院（生物医学工程学院）、附属眼视光医院_眼底外科（含眼外伤专科）
通讯作者	Jin, Xiance
作者单位	1.Departments of Gynecology,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou,325000,China; 2.Departments of Radiation Oncology and Chemotherapy,The First Affiliated Hospital,Wenzhou Medical University,Wenzhou,325000,China; 3.Departments of Eye Fundus Surgery,Eye hospital of Wenzhou Medical University,Wenzhou,325002,China
第一作者单位	附属第一医院
通讯作者单位	附属第一医院
第一作者的第一单位	附属第一医院
推荐引用方式 GB/T 7714	Zhao, Hongqin,Li, Lili,Su, Huafang,et al. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study[J]. ONCOTARGET,2016,7(43):70969-70978.
APA	Zhao, Hongqin., Li, Lili., Su, Huafang., Lin, Baochai., Zhang, Xuebang., ... & Xie, Congying. (2016). Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study. ONCOTARGET, 7(43), 70969-70978.
MLA	Zhao, Hongqin,et al."Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study".ONCOTARGET 7.43(2016):70969-70978.